{"id":9895,"date":"2026-07-28T17:22:12","date_gmt":"2026-07-28T22:22:12","guid":{"rendered":"https:\/\/fifarma.org\/?post_type=publicaciones&p=9895"},"modified":"2026-07-28T17:36:47","modified_gmt":"2026-07-28T22:36:47","slug":"fifarma-wait-indicator-brazil-2026","status":"publish","type":"publicaciones","link":"https:\/\/fifarma.org\/pt\/publicaciones\/fifarma-wait-indicator-brazil-2026\/","title":{"rendered":"FIFARMA W.A.I.T. Indicator 2026 – Brazil"},"content":{"rendered":"

The Patient W.A.I.T. Indicator 2026 \u2013 Brazil, developed by FIFARMA in collaboration with IQVIA, analyzes the availability of and access to innovative medicines in the country. The study shows that only 19% of innovative molecules are fully available in Brazil, while the average time to access reaches 5.5 years. The report identifies the main barriers affecting access, as well as opportunities to improve the availability of innovation to patients.<\/p>\n\n\n\n

View document<\/a><\/strong><\/p>","protected":false},"author":24,"parent":0,"template":"","ano":[187],"idioma":[45],"etiquetas-publicacion":[173,89],"categoria-publicacion":[37,29],"class_list":["post-9895","publicaciones","type-publicaciones","status-publish","hentry","ano-187","idioma-english","etiquetas-publicacion-wait","etiquetas-publicacion-wait-indicator","categoria-publicacion-informe-pais","categoria-publicacion-reporte"],"yoast_head":"\nFIFARMA W.A.I.T. Indicator 2026 - Brazil<\/title>\n<meta name=\"description\" content=\"FIFARMA W.A.I.T. Indicator 2026: Analysis of innovative medicines in Brazil, access barriers, and data on 447 approved molecules.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fifarma.org\/pt\/publicacoes\/fifarma-wait-indicator-brazil-2026\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FIFARMA W.A.I.T. Indicator 2026 - Brazil\" \/>\n<meta property=\"og:description\" content=\"FIFARMA W.A.I.T. Indicator 2026: Analysis of innovative medicines in Brazil, access barriers, and data on 447 approved molecules.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fifarma.org\/pt\/publicacoes\/fifarma-wait-indicator-brazil-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"FIFARMA\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-28T22:36:47+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/fifarma-wait-indicator-brazil-2026\\\/\",\"url\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/fifarma-wait-indicator-brazil-2026\\\/\",\"name\":\"FIFARMA W.A.I.T. Indicator 2026 - Brazil\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#website\"},\"datePublished\":\"2026-07-28T22:22:12+00:00\",\"dateModified\":\"2026-07-28T22:36:47+00:00\",\"description\":\"FIFARMA W.A.I.T. Indicator 2026: Analysis of innovative medicines in Brazil, access barriers, and data on 447 approved molecules.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/fifarma-wait-indicator-brazil-2026\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/fifarma-wait-indicator-brazil-2026\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/fifarma-wait-indicator-brazil-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/fifarma.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publicaciones\",\"item\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"FIFARMA W.A.I.T. Indicator 2026 – Brazil\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#website\",\"url\":\"https:\\\/\\\/fifarma.org\\\/\",\"name\":\"FIFARMA\",\"description\":\"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica\",\"publisher\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fifarma.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#organization\",\"name\":\"Fifarma\",\"alternateName\":\"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica\",\"url\":\"https:\\\/\\\/fifarma.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/logo-fifarma.png\",\"contentUrl\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/logo-fifarma.png\",\"width\":195,\"height\":39,\"caption\":\"Fifarma\"},\"image\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FIFARMA W.A.I.T. Indicator 2026 - Brazil","description":"FIFARMA W.A.I.T. Indicator 2026: Analysis of innovative medicines in Brazil, access barriers, and data on 447 approved molecules.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fifarma.org\/pt\/publicacoes\/fifarma-wait-indicator-brazil-2026\/","og_locale":"pt_BR","og_type":"article","og_title":"FIFARMA W.A.I.T. Indicator 2026 - Brazil","og_description":"FIFARMA W.A.I.T. Indicator 2026: Analysis of innovative medicines in Brazil, access barriers, and data on 447 approved molecules.","og_url":"https:\/\/fifarma.org\/pt\/publicacoes\/fifarma-wait-indicator-brazil-2026\/","og_site_name":"FIFARMA","article_modified_time":"2026-07-28T22:36:47+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. tempo de leitura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/fifarma.org\/publicaciones\/fifarma-wait-indicator-brazil-2026\/","url":"https:\/\/fifarma.org\/publicaciones\/fifarma-wait-indicator-brazil-2026\/","name":"FIFARMA W.A.I.T. Indicator 2026 - Brazil","isPartOf":{"@id":"https:\/\/fifarma.org\/#website"},"datePublished":"2026-07-28T22:22:12+00:00","dateModified":"2026-07-28T22:36:47+00:00","description":"FIFARMA W.A.I.T. Indicator 2026: Analysis of innovative medicines in Brazil, access barriers, and data on 447 approved molecules.","breadcrumb":{"@id":"https:\/\/fifarma.org\/publicaciones\/fifarma-wait-indicator-brazil-2026\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fifarma.org\/publicaciones\/fifarma-wait-indicator-brazil-2026\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fifarma.org\/publicaciones\/fifarma-wait-indicator-brazil-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/fifarma.org\/"},{"@type":"ListItem","position":2,"name":"Publicaciones","item":"https:\/\/fifarma.org\/publicaciones\/"},{"@type":"ListItem","position":3,"name":"FIFARMA W.A.I.T. Indicator 2026 – Brazil"}]},{"@type":"WebSite","@id":"https:\/\/fifarma.org\/#website","url":"https:\/\/fifarma.org\/","name":"FIFARMA","description":"Federa\u00e7\u00e3o Latino-Americana da Ind\u00fastria Farmac\u00eautica","publisher":{"@id":"https:\/\/fifarma.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fifarma.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/fifarma.org\/#organization","name":"Fifarma","alternateName":"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica","url":"https:\/\/fifarma.org\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/fifarma.org\/#\/schema\/logo\/image\/","url":"https:\/\/fifarma.org\/wp-content\/uploads\/2022\/10\/logo-fifarma.png","contentUrl":"https:\/\/fifarma.org\/wp-content\/uploads\/2022\/10\/logo-fifarma.png","width":195,"height":39,"caption":"Fifarma"},"image":{"@id":"https:\/\/fifarma.org\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/publicaciones\/9895","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/publicaciones"}],"about":[{"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/types\/publicaciones"}],"author":[{"embeddable":true,"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/users\/24"}],"wp:attachment":[{"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/media?parent=9895"}],"wp:term":[{"taxonomy":"ano","embeddable":true,"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/ano?post=9895"},{"taxonomy":"idioma","embeddable":true,"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/idioma?post=9895"},{"taxonomy":"etiquetas-publicacion","embeddable":true,"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/etiquetas-publicacion?post=9895"},{"taxonomy":"categoria-publicacion","embeddable":true,"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/categoria-publicacion?post=9895"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}